COVID-19 Vaccine Messaging, Part 1
NCT04460703 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4000
Last updated 2022-05-05
Summary
This study tests different messages about vaccinating against COVID-19 once the vaccine becomes available. Participants are randomized to 1 of 12 arms, with one control arm and one baseline arm. We will compare the reported willingness to get a COVID-19 vaccine at 3 and 6 months of it becoming available between the 10 intervention arms to the 2 control arms.
Study participants are recruited online by Lucid, which matches census based sampling in online recruitment.
Conditions
- Vaccination
- COVID-19
Interventions
- OTHER
-
Control message
2/15 of the sample will be assigned to the pure control group, which is a passage on the costs and benefits of bird feeding.
- OTHER
-
Baseline message
3/15 of the sample will be assigned to a control group with a message about the effectiveness and safety of vaccines.
- OTHER
-
Personal freedom message
1/15 of the sample will be assigned to this intervention, which is a message about how COVID-19 is limiting people's personal freedom and by working together to get enough people vaccinated society can preserve its personal freedom.
- OTHER
-
Economic freedom message
1/15 of the sample will be assigned to this intervention, which is a message about how COVID-19 is limiting peoples's economic freedom and by working together to get enough people vaccinated society can preserve its economic freedom.
- OTHER
-
Self-interest message
1/15 of the sample will be assigned to this intervention, which is a message that COVID-19 presents a real danger to one's health, even if one is young and healthy. Getting vaccinated against COVID-19 is the best way to prevent oneself from getting sick.
- OTHER
-
Community interest message
1/15 of the sample will be assigned to this intervention, which is a message about the dangers of COVID-19 to the health of loved ones. The more people who get vaccinated against COVID-19, the lower the risk that one's loved ones will get sick. Society must work together and all get vaccinated.
- OTHER
-
Economic benefit message
1/15 of the sample will be assigned to this group, which is a message about how COVID-19 is wreaking havoc on the economy and the only way to strengthen the economy is to work together to get enough people vaccinated.
- OTHER
-
Guilt message
1/15 of the sample will be assigned to this message. The message is about the danger that COVID-19 presents to the health of one's family and community. The best way to protect them is by getting vaccinated and society must work together to get enough people vaccinated. Then it asks the participant to imagine the guilt they will feel if they don't get vaccinated and spread the disease.
- OTHER
-
Embarrassment message
1/15 of the sample will be assigned to this message. The message is about the danger that COVID-19 presents to the health of one's family and community. The best way to protect them is by getting vaccinated and by working together to make sure that enough people get vaccinated. Then it asks the participant to imagine the embarrassment they will feel if they don't get vaccinated and spread the disease.
- OTHER
-
Anger message
1/15 of the sample will be assigned to this message. The message is about the danger that COVID-19 presents to the health of one's family and community. The best way to protect them is by getting vaccinated and by working together to make sure that enough people get vaccinated. Then it asks the participant to imagine the anger they will feel if they don't get vaccinated and spread the disease.
- OTHER
-
Trust in science message
1/15 of the sample will be assigned to this message about how getting vaccinated against COVID-19 is the most effective way of protecting one's community. Vaccination is backed by science. If one doesn't get vaccinated that means that one doesn't understand how infections are spread or who ignores science.
- OTHER
-
Not bravery message
1/15 of the sample will be assigned to this message which describes how firefighters, doctors, and front line medical workers are brave. Those who choose not to get vaccinated against COVID-19 are not brave.
Sponsors & Collaborators
-
Yale University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-07-03
- Primary Completion
- 2020-07-08
- Completion
- 2020-07-08
Countries
- United States
Study Locations
More Related Trials
-
Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 Years
NCT06314685 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
The Impact of Vaccination on Severity of Illness in COVID-19
NCT04912700 ·Status: COMPLETED
-
Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis
NCT01482052 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase III Clinical Trial of the Group A and C Meningococcal Polysaccharide Vaccine
NCT04689191 ·Status: UNKNOWN ·Phase: PHASE3
-
A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19
NCT04540185 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age
NCT04796896 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Text Message Reminder-Recalls For Early Childhood Vaccination
NCT01199666 ·Status: COMPLETED ·Phase: NA
-
Educational Intervention to Improve Vaccine Acceptance
NCT01385501 ·Status: COMPLETED ·Phase: NA
-
Improving the School Vaccination Experience: What CARDs Are You Going to Play?
NCT03966300 ·Status: TERMINATED ·Phase: NA
-
Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants
NCT02692599 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
NCT00422292 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy Trial of a Commercial EV71 Vaccine
NCT03903926 ·Status: COMPLETED ·Phase: PHASE4
-
A Phase III Clinical Trial of the Group A Meningococcal Polysaccharide Vaccine
NCT04689165 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine
NCT06337071 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years
NCT04450498 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of an EV71 Vaccine
NCT03865238 ·Status: COMPLETED ·Phase: PHASE3
-
Text4Vax: Text Message Reminders for Pediatric COVID-19 and Influenza Vaccines 2024-25 Season
NCT06603090 ·Status: COMPLETED ·Phase: NA
-
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
NCT06592794 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age
NCT01461980 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults
NCT02669121 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity and Safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in Volunteers Aged 3-5 Months
NCT06314659 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
NCT05543616 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old
NCT04714229 ·Status: COMPLETED ·Phase: PHASE1
-
Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Nonpregnant Women And Pregnant Women And Their Infants
NCT03765073 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I Clinical Trial of Inactivated Rotavirus Vaccine in a Population Aged 6 Weeks-49 Years Old
NCT06350058 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1